Stroke recovery may depend more on the type of vascular blockage than previously understood, with important implications for targeting brain immune responses during treatment. New mechanistic research reveals that a key microglial protein called Trem2 can either protect or harm the brain depending on how stroke occurs, challenging assumptions about uniform therapeutic approaches.
Using a photothrombotic stroke model that mimics small vessel occlusions, investigators found that Trem2 actually worsens brain damage by activating the Gpnmb protein pathway. This contrasts sharply with previous findings showing Trem2's protective effects in large vessel stroke models. The research demonstrates that Trem2-deficient mice experienced significantly less brain tissue death and better functional outcomes when subjected to light-induced clotting in small cerebral vessels. The mechanism involves Trem2 triggering Gpnmb expression, which then amplifies destructive microglial responses rather than promoting tissue repair.
This finding has profound implications for stroke therapeutics, as it suggests that microglial modulation strategies must account for stroke subtype. Small vessel disease represents roughly 25% of all strokes and disproportionately affects aging populations. The discovery that the same protein can be beneficial or detrimental depending on vessel size and occlusion mechanism indicates that precision medicine approaches will be essential for neuroinflammation targets. Current clinical trials testing Trem2 agonists for neurological conditions may need to stratify patients by stroke type. The research also highlights Gpnmb as a potential therapeutic target, since blocking this downstream effector might preserve Trem2's beneficial functions while eliminating its harmful effects in small vessel contexts.